Affymax (AFFY) Continues Ripping on New OMONTYS Sourcing Agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax, Inc. (Nasdaq: AFFY) is making a run for the second session Friday, following news on Thursday that partner Takeda Pharmaceuticals entered a supply agreement with for sourcing and supply of OMONTYS (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates.
Shares are now up 37 percent over two days and 14.5 percent on Friday.
Shares are now up 37 percent over two days and 14.5 percent on Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lumentum's optical components sold out through early 2029: CEO
- Musk rules out TSMC role in Terafab operations; Intel gains
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
